Results 131 to 140 of about 1,261,678 (381)

Timing and Predictive Value of Clinical Conditions Preceding Multiple Sclerosis in the UK Biobank

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives Multiple sclerosis (MS) patients often experience a higher incidence of clinical conditions before diagnosis, suggesting a prodromal phase. However, their predictive value and temporal trajectories remain underexplored. We investigated these aspects using the large UK Biobank's population‐based cohort, which provided clinical ...
Andrea Nova, Teresa Fazia, Giovanni Di Caprio, Davide Gentilini, Luisa Bernardinelli, Roberto Bergamaschi   +5 more
wiley   +1 more source

Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels. Methods Patients with FIRES admitted to the Intensive Care Unit (ICU) of Beijing Children's Hospital were retrospectively ...
Yushan He, Jie Wu, Chaonan Fan, Zheng Li, Jun Liu, Kechun Li, Quan Wang, Suyun Qian   +7 more
wiley   +1 more source

Cerebrospinal Fluid Biomarkers in Differential Diagnosis of Multiple Sclerosis and Systemic Inflammatory Diseases with Central Nervous System Involvement. [PDF]

Biomedicines, 2023
Świderek-Matysiak M, Oset M, Domowicz M, Galazka G, Namiecińska M, Stasiołek M.   +5 more
europepmc   +1 more source

The results of clinical research on the effects of plants on nervous system diseases [PDF]

, 2019
Istraživanja bez sumnje pokazuju da u biljkama ima skoro beskonačno rezervi kemijskih tvari sa stvarnim i potencijalnim efektima na ljudsko tijelo. Postoji tek nekoliko istraživanja koja se provode u uvjetima u kojima se kontrolira placebo efekt. Sama
Martinec, Ivana
core   +2 more sources

Understanding Mechanisms of Whole Brain and Regional Grey Matter Atrophy in Children With MOGAD

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To investigate the mechanisms driving whole brain and regional grey matter (GM) volume changes along with their clinical correlates in paediatric myelin oligodendrocyte glycoprotein antibody (MOG‐Ab)–associated disease (MOGAD). Methods One‐hundred‐nine paediatric MOGAD patients from two UK centres underwent MRI at attack nadir and ...
Ermelinda De Meo, Riccardo Nistri, Michael Eyre, Cheryl Hemingway, Ming Lim, Thomas Rossor, Asthik Biswas, Kshitij Mankad, Ata Siddiqui, Sniya Sudhakar, Declan Chard, Frederik Barkhof, Arman Eshaghi, Olga Ciccarelli, Yael Hacohen   +14 more
wiley   +1 more source

[Viral diseases of the nervous system-Selected new and old viruses]. [PDF]

Nervenarzt, 2023
Meyding-Lamadé U, Craemer EM.
europepmc   +1 more source

High‐Efficacy Treatment in Neuromyelitis Optica Specturm Disorder Patients With Seropositive AQP4 Antibodies—A Real‐World Study

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To compare the effectiveness of high‐efficacy treatments (HET) and low‐efficacy treatments (LET) in NMOSD patients with anti‐aquaporin‐4 antibodies (AQP4‐ab). Methods In this multi‐center study, we analyzed 183 AQP4‐ab seropositive NMOSD patients who received immunosuppressive treatments (IST).
Xiang Li, Binbin Xue, Jia Li, Dewei Xie, Juyuan Pan, Lanbing Zhu, Qiaowen Tong, Jing Lin, Xu Zhang, Junhui Xia, Jie Lin   +10 more
wiley   +1 more source

An Ecological Analysis of Hospitalization Patterns for Diseases of the Nervous System in England and Wales over the Last 20 Years. [PDF]

Healthcare (Basel), 2022
Naser AY, Dahmash EZ, Al-Daghastani T, Alwafi H, Abu Hamdah S, Alsairafi ZK, Alsaleh FM, Alsaleh FM.   +7 more
europepmc   +1 more source

Real‐World Comparison of High‐Efficacy Versus Non‐High‐Efficacy Therapies in Multiple Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective The choice of the first disease modifying treatment (DMT) in multiple sclerosis (MS) is a topic of great interest, and whether high‐efficacy DMTs should be the first choice remains debated. We compared treatment outcomes (no evidence of disease activity [NEDA] and its components) between treatment‐naïve relapsing–remitting MS (RRMS ...
Sarmad Al‐Araji, Marcello Moccia, Alessia Bianchi, Charmaine Yam, Weaam Hamed, Suraya Mohamud, Alan J. Thompson, Frederik Barkhof, Ahmed T. Toosy, Olga Ciccarelli   +9 more
wiley   +1 more source

DISEASES OF THE NERVOUS SYSTEM

The Journal OF Nervous and Mental Disease, 1908
Mode of access: Internet.
openaire   +3 more sources